Your missing links are here (21 February 2020)

Some of the best stuff we picked up around the Internet

By: Rasmus Kragh Jakobsen - Feb. 21, 2020

RNA editing is taking off. CRISPR make room.
Interview with Carl June on CRISPR, CAR–T and how the Vietnam War dropped him into medicine.
Using a CRISPR–Cas9 genome-wide screen to uncover unique T-cell, that gives hope for universal cancer therapies.
Should we rewrite our DNA? The Guardian and Wellcome look at the future of CRISPR and genome editing. Podcast and video - The Gene Gap - informs and asks You to share your views on how we should use it?

CRISPR gene editing appears safe in the first US Human Safety Trial. Using genetically-edited cells to supercharge the immune system caused no adverse effects in cancer patients. It's too soon to tell if it can be a cure.
Perspective by Doudna and Hamilton: CRISPR-Cas9 gene-edited T cells show safety and long-term engraftment in humans

Building better base editors, new research from the Liu-lab brings base-editors that make fewer off-targets and access more genome locations.
A new CRISPR-based tool can probe and control several genetic circuits at once.
A CRISPR cure for cystic fibrosis?
Unwanted CRISPR-Cas9 duplications and warning to researchers.

Great piece by Yangyang Cheng gathers the threads that connect CRISPR-baby scientist He Jiankui, Chinese hospitals and patient violence, the coronavirus and lockdown of Wuhan, politics and his family history.
From mice to dogs, and someday man: George Church's gene therapy cocktail for aging-related diseases.

BioMarin's pioneering hemophilia gene therapy secures priority review by the FDA.
Gene therapy pioneer Kathy High has left the drug giant Roche just two months after it purchased the company she founded, Spark Therapeutics, for $4.3 billion.
Belgian Biotech Raises €50M to Make Gene Therapy Manufacturing Cheaper.
The European Patent Office (EPO) has affirmed a patent issued to CRISPR pioneer Emmanuelle Charpentier, rejecting arguments filed in opposition by the Broad Institute of MIT and Harvard.
Base Editing Drug Developer, Beam Therapeutics Raises $180M in IPO.
Global CRISPR Genome Editing Market Set For Rapid Growth.

Curious about the new online resource - The Global Gene Regulation Tracker - from the Genetic Literacy Project? Listen to The Talking Biotech podcast.
UK Parliamentary Office publishes brief on human germline genome editing.